ALPHANET Canadian Trademark Information

On Wednesday, November 12, 2008, a canadian trademark registration was filed for ALPHANET by AlphaNet Canada *********, **********, ***** ****. The Canadian IP office has given the trademark application number of 1418024. The current status of this trademark filing is Registration published. The ALPHANET trademark is filed in the description of Charitable services, namely, providing financial support for clinical research to improve the lives of individuals affected by Alpha-1 Antitrypsin Deficiency; education services, namely, providing classes, seminars, and workshops in the field Alpha-1 Antitrypsin Deficiency; providing on-line publications in the nature of guides and newsletters in the field of Alpha-1 Antitrypsin Deficiency; training of study staff in the field of Alpha-1 Antitrypsin Deficiency and clinical trials; providing medical and scientific research information in the field of Alpha-1 Antitrypsin Deficiency; consultation services in the field of facilitating and conducting clinical trials involving human subjects of new treatment options for individuals affected by Alpha-1 Antitrypsin Deficiency in the nature of identifying qualified study sites and researchers and encouraging study enrollment; health care services, namely, disease management for individuals affected by Alpha-1 Antitrypsin Deficiency; providing support and assistance services to inform individuals affected by Alpha-1 Antitrypsin Deficiency about the range of possible diagnoses and therapies to improve the quality of their lives; providing links to the web sites of others featuring information about the diagnosis, management and treatment of Alpha-1 Antitrypsin Deficiency; providing health and medical care information to individuals affected by Alpha-1 Antitrypsin Deficiency about the range of possible diagnoses and therapies to improve the quality of their lives; providing support and assistance, namely counselling services, to individuals affected by Alpha-1 Antitrypsin Deficiency. , Charitable services, namely, providing financial support for clinical research to improve the lives of individuals affected by Alpha-1 Antitrypsin Deficiency; education services, namely, providing classes, seminars, and workshops in the field Alpha-1 Antitrypsin Deficiency; providing on-line publications in the nature of guides and newsletters in the field of Alpha-1 Antitrypsin Deficiency; training of study staff in the field of Alpha-1 Antitrypsin Deficiency and clinical trials; providing medical and scientific research information in the field of Alpha-1 Antitrypsin Deficiency; consultation services in the field of facilitating and conducting clinical trials involving human subjects of new treatment options for individuals affected by Alpha-1 Antitrypsin Deficiency in the nature of identifying qualified study sites and researchers and encouraging study enrollment; providing quality assurance services in the field of clinical trials by generating and monitoring study data and documentation thereof for quality assurance purposes; health care services, namely, disease management for individuals affected by Alpha-1 Antitrypsin Deficiency; providing support and assistance services to inform individuals affected by Alpha-1 Antitrypsin Deficiency about the range of possible diagnoses and therapies to improve the quality of their lives; providing links to the web sites of others featuring information about the diagnosis, management and treatment of Alpha-1 Antitrypsin Deficiency; providing health and medical care information to individuals affected by Alpha-1 Antitrypsin Deficiency about the range of possible diagnoses and therapies to improve the quality of their lives; providing support and assistance, namely counselling services, to individuals affected by Alpha-1 Antitrypsin Deficiency; identifying qualified study sites, namely, inspection of laboratory research facilities for safety purposes , Downloadable electronic publications in the nature of informational and educational materials, namely booklets, in the field of Alpha-1 Antitrypsin Deficiency; downloadable multimedia files containing artwork, text, audio and video in the field of Alpha-1 Antitrypsin Deficiency; pre-recorded electronic media, namely CDs, DVDs, thumb drives and video tapes in the field of Alpha-1 Antitrypsin Deficiency; printed informational and educational materials, namely, booklets and reference guides, in the field of Alpha-1 Antitrypsin Deficiency , Charitable services, namely, providing financial support for clinical research to improve the lives of individuals affected by Alpha-1 Antitrypsin Deficiency; education services, namely, providing classes, seminars, and workshops in the field Alpha-1 Antitrypsin Deficiency; providing on-line publications in the nature of guides and newsletters in the field of Alpha-1 Antitrypsin Deficiency; training of study staff in the field of Alpha-1 Antitrypsin Deficiency and clinical trials; providing medical and scientific research information in the field of Alpha-1 Antitrypsin Deficiency; consultation services in the field of facilitating and conducting clinical trials involving human subjects of new treatment options for individuals affected by Alpha-1 Antitrypsin Deficiency in the nature of , Downloadable electronic publications in the nature of informational and educational materials, namely booklets, in the field of Alpha-1 Antitrypsin Deficiency; downloadable multimedia files containing artwork, text, audio and video in the field of Alpha-1 Antitrypsin Deficiency; pre-recorded electronic media, namely CDs, DVDs, thumb drives and video tapes in the field of Alpha-1 Antitrypsin Deficiency; printed informational and educational materials, namely, booklets and reference guides, in the field of Alpha-1 Antitrypsin Deficiency , Charitable services, namely, providing financial support for clinical research to improve the lives of individuals affected by Alpha-1 Antitrypsin Deficiency; education services, namely, providing classes, seminars, and workshops in the field Alpha-1 Antitrypsin Deficiency; providing on-line publications in the nature of guides and newsletters in the field of Alpha-1 Antitrypsin Deficiency; training of study staff in the field of Alpha-1 Antitrypsin Deficiency and clinical trials; providing medical and scientific research information in the field of Alpha-1 Antitrypsin Deficiency; consultation services in the field of facilitating and conducting clinical trials involving human subjects of new treatment options for individuals affected by Alpha-1 Antitrypsin Deficiency in the nature of .